Related Experiment Videos
Doxorubicin and dactinomycin therapy for advanced sarcomas
Cancer Treatment Reports
|March 1, 1981
Summary
The combination of doxorubicin and dactinomycin showed a 28% response rate in advanced sarcomas but increased toxicity. This regimen is less desirable than doxorubicin alone due to significant side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced sarcomas are challenging to treat.
- Doxorubicin and dactinomycin are established chemotherapy agents.
Purpose of the Study:
- To evaluate the efficacy and toxicity of combined doxorubicin and dactinomycin in advanced sarcomas.
- To compare this combination therapy with doxorubicin alone.
Main Methods:
- Administered doxorubicin and dactinomycin to 25 patients with advanced sarcomas.
- Evaluated response rates, survival, and toxic effects.
- Analyzed plasma doxorubicin kinetics in a subset of patients.
Main Results:
- Achieved a 28% response rate (2 complete, 4 partial) in 21 evaluable patients.
- Responders demonstrated longer survival; intermediate survival for those with improvements.
- Significant toxicities included leukopenia (35%), mucositis (50%), and congestive heart failure (21%).
Conclusions:
- The combination therapy showed comparable response rates to doxorubicin alone.
- Increased toxicity with the combination regimen makes it less desirable.
- Doxorubicin monotherapy is preferred over the combination due to a better toxicity profile.